6.4.1.1. Oestrogens and HRT
6.4.1.1.1. Combination products
For use in women with an intact uterus
6.4.1.1.1.1. Sequential combined therapy (cyclical)
Last menstrual period <1 year ago
Prescribing Notes:
Combination of EvorelĀ® 50 patches (containing estradiol) and EvorelĀ® Conti patches (estradiol and norethisterone acetate).
Prescribing Notes:
Tablet available as 1mg/10mg and 2mg/10mg strengths. Contains estradiol and dydrogesterone.
6.4.1.1.1.2. Continuous combined therapy
Last menstrual period >1 year ago
Prescribing Notes:
Transdermal patch containing estradiol 50mcg /24 hours and norethisterone acetate 170mcg / 24 hours.
Prescribing Notes:
Tablet available as 0.5mg/2.5mg and 1mg/5mg strengths. Contains estradiol and dydrogesterone.
6.4.1.1.2. Oestrogen only
For use in women with no uterus or using an alternative progesterone
Prescribing Notes:
Transdermal patch containing estradiol. Available in 25, 50, 75 and 100 micrograms/24hour strengths.
Prescribing Notes:
Transdermal patch containing estradiol. Available in 25, 37.5, 50, 75 and 100 micrograms/24hour strengths.
Restrictions:
Restricted to patients who fail to tolerate oral or patch preparations.
Prescribing Notes:
Strength: 0.06%
6.4.1.1.3. Gonadomimetic
Prescribing Notes:
Tablets used for the short-term treatment of symptoms of oestrogen deficiency. Unsuitable for use in the premenopause (unless being treated with gonadotrophin-releasing hormone analogue) and as (or with) an oral contraceptive. Also unsuitable for use within 12 months of last menstrual period (may cause irregular bleeding).
If transferring from cyclical HRT, start at end of regimen; if transferring from continuous-combined HRT, start at any time.